Baijin Life Science Holdings Limited (Stock Code: 1466) announced that it has completed the allotment and issuance of 40,000,000 new shares under a General Mandate on 28 November 2025. The subscription price was HK$0.48 per share, leading to gross proceeds of HK$19.2 million and net proceeds of approximately HK$19.1 million. According to the company, 60% of the net proceeds is earmarked for repayment of bank borrowings, other borrowings, and payables, while the remaining 40% will serve as general working capital.

Following this issuance, the total number of shares in issue increased from 892,254,085 to 932,254,085. Ketto Inform Limited recorded an approximate 17.14% shareholding, while Pacific Wish Limited holds around 9.02%. The newly issued shares have been allocated among three subscribers, resulting in adjusted shareholdings and expanded capital base.